Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback